About
Dr. Samarth Kulkarni is the Chief Executive Officer of CRISPR Therapeutics. He has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer and then was appointed to President and Chief Business Officer before becoming CEO. Before joining our company, Sam was a Partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice, where he focused on strategy and operations, and led initiatives in areas such as personalized medicine and immunotherapy. Previously, Sam served as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR Therapeutics and Bayer. Sam currently serves on the Board of Directors of two precision oncology companies, Black Diamond Therapeutics, and Repare Therapeutics. He receiv
Position in the VCSift Database
- • 2 investors at CRISPR Therapeutics are tracked.
- • 1,305 investors hold the Chief Executive Officer role in VCSift. Samarth Kulkarni is one of them.
- • 2,799 investors are based in United States.
Data sourced from 410,343 investor profiles. Updated June 2026.
Investment Focus
- Location
- US
Contact Information
Find more investors like Samarth
Search Investors